Gsk Share Discussion Threads

[suresure] 26/2/2020 23:45

Gsk price has FA to do with Coronavirus, no exposure. Everything to do with Sales growth, debt, value post spin off. DYOR.

[tradermichael] 26/2/2020 15:32

Agree, specifically pharmaceuticals like GSK. Everyone needs prescription medicines in times like this (supposed to be a "defensive" stock ???).

GSK has the key to scale-up of a vaccine for CoViD-19 with its adjuvant technology, so there is every reason to say that this sell-off is over-reactive!

[tim 3] 26/2/2020 13:48

Sell off well overdone not just here but on many other stocks.imo

Would add here but already got my full allocation.

[nimbo1] 26/2/2020 13:38

bought in this am

[grahamburn] 25/2/2020 15:01

From The Times Business News today:

CORONAVIRUS
Glaxosmithkline works with China to find vaccine
Alex Ralph
Tuesday February 25 2020, 12.01am, The Times

Glaxosmithkline will provide Clover, a Chinese biotech company, with technology to research a potential vaccine

One of Britain’s biggest drugs companies is partnering with a Chinese biotech company to develop its vaccine candidate for the coronavirus.

Glaxosmithkline will provide Clover Biopharmaceuticals with its adjuvant technology to help research Clover’s vaccine candidate in pre-clinical studies.

The collaboration is one of a number launched by drugs companies and research institutes since the coronavirus emerged towards the end of last year in China. Earlier this month Glaxo also entered into collaboration with the University of Queensland in Australia to develop an effective vaccine.

The partnership with Clover could potentially mean supplying any vaccine more efficiently, since the Chinese company has one of the largest “inhouse, commercial scale” biomanufacturing capabilities in China. The companies said that it meant that Clover could rapidly scale up rapidly and produce large quantities of a new coronavirus vaccine.

The World Health Organisation (WHO) has declared the coronavirus a public health emergency and China has reported 76,936 cases and 2,442 deaths.

Concerns about the impact on the Chinese and global economies and the spread of the disease has unsettled global financial markets and supply chains.

Reports this month had raised hopes of drug breakthroughs. However, the WHO has clarified that there are “no known effective therapeutics” against the virus.

Thomas Breuer, chief medical officer at Glaxo’s vaccines business, has said that it will take at least 12 to 18 months to develop and get regulatory approval for a vaccine.

Glaxo is based in west London and is a constituent of the FTSE 100 index, valued at £83.2 billion. It generated sales of £33.8 billion last year, including £7.2 billion from its vaccines business, which includes treatments such as Shingrix for shingles as well as meningitis vaccines.

Emma Walmsley, Glaxo’s chief executive, said this month when the University of Queensland collaboration was announced that the company stood ready to work with other institutions and companies “wherever we can”. She added that Glaxo’s scientists were screening “everything that we have within the portfolio”.

Glaxo develops vaccines using different adjuvant systems, which are added to enhance the body’s immune response to create a stronger and longer lasting immunity against infections than the vaccine alone.

Dr Breuer said this morning that Clover’s vaccines candidate was promising and that “the use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people”.

Clover is a clinical-stage, research-based biotech company focused on oncology and autoimmune diseases and viral vaccines. It has raised more than $100 million since 2016.

Steven Gong, vice president of business development and strategy at Clover, said: “Collaborations will be critical to accelerating the development of a successful new vaccine in times of emergency, and we continue to invite any interested regulatory, academic or industry parties to contact us for this noble common cause.”

[crossing_the_rubicon] 25/2/2020 09:21

Gilead Surges After WHO Comments on Coronavirus Drug Testing

Remdesivir is the “one drug right now that we think may have efficacy,” Bruce Aylward, an assistant director-general at the World Health Organization, said at a briefing in Beijing. WHO officials and international scientists are in the country assessing the outbreak.




The spread of the coronavirus accelerated internationally over the weekend with exponential growth in South Korea and Italy. Right now, there are no cures for the ailment and therefore any whiff of a successful treatment is likely to be rewarded with investor interest.

[spud] 24/2/2020 15:47

From Cramer column today:Cramer sees biotech stocks as a refuge in the coronavirus-driven market plungeGlaxoSmithKline is another example of a stock that could remain attractive, Cramer said. He said the British pharmaceutical company has new developments around its anti-cancer efforts and it maintains a strong dividend yield.spud

[crossing_the_rubicon] 24/2/2020 15:26

Handelsblatt also reported overnight that Stada will takes over 15 of Glaxo's branded products for more than €300M.

[rikky72] 24/2/2020 11:59

Is this liable to sink further or stay in the doldrums or do people see a recovery in next few months? Interested to hear perspectives..

[igoe104] 22/2/2020 14:43

Why are ADVFN letting this idiot, post over 13 pages of spam ?

[prambigear] 22/2/2020 14:17

sod off lily

[zho] 22/2/2020 07:51

"Scientists from multiple countries have published and analysed genomes of the causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),1
and they overwhelmingly conclude that this coronavirus originated in wildlife ....
as have so many other emerging pathogens..... Conspiracy theories do nothing but create fear, rumours, and prejudice that jeopardise our global collaboration in the fight against this virus."

[milehouse] 21/2/2020 12:40

EI,
Thanks, this is what I guessed. Just didn't want to be missing something glaringly obvious!

[essentialinvestor] 21/2/2020 12:17

mile, this is just guessing, but GSK slightly disappointed I think on outlook.

With GSK, it goes through large sentiment swings from investors getting excited
to ...it's the end of the world as we know it.

Sentiment alone can have a large impact on share prices, without much change in fundamentals.

From an investment or trading view, you can sometimes take advantage of that volatility.

Michael, who posts here, has done that for years!.

[milehouse] 21/2/2020 12:13

EI,
I completely agree with the AZ position vs GSK, for the next few years they are in the better position. This was pretty much all already known though correct? The results didn't change this?

[essentialinvestor] 21/2/2020 11:40

milehouse, look at the forward earnings guidance given re GSK v AZN.

There is little comparison atm, AZN is enjoying a purple patch.

Astra Net debt is also approx 50% lower than GSK.

[beckers2008] 21/2/2020 11:29

M,

Adjusted profit fell short of forecasts, seems the shine has come off GSK and market is selling it down.
Market expecting great things of EW, but now she has also stated the proposed alliance will cost GSK £2.4b.

[spud] 21/2/2020 11:03

Similar to the performance of RDSB v BP.

spud

[milehouse] 21/2/2020 11:00

Can anyone explain why this stock has performed so poorly since results?

If we compare it to AZ, results were better and the hit has been far greater. The exposure that AZ has to China and the coronavirus too is monumental, they are the largest pharma there.

GSK is down >10% since the results and AZ is higher...?!

[daveboy1] 21/2/2020 10:40

Well, I was holding at average £14.50 last summer, so anything goes in my experience.